このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

全身性エリテマトーデスの参加者におけるオビヌツズマブの有効性と安全性を評価する研究 (ALLEGORY)

2026年11月10日 更新者:Hoffmann-La Roche

全身性エリテマトーデス患者におけるオビヌツズマブの有効性と安全性を評価する第 III 相無作為化二重盲検プラセボ対照多施設試験

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

調査の概要

研究の種類

介入

入学 (実際)

303

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Anniston、Alabama、アメリカ、36207
        • Pinnacle Research Group
    • Arkansas
      • Searcy、Arkansas、アメリカ、72143
        • Unity Health - White County Medical Center- Rheumatology
    • California
      • Fullerton、California、アメリカ、92835
        • Providence Medical Foundation
    • Florida
      • Aventura、Florida、アメリカ、33180
        • Arthritis & Rheumatism
    • Michigan
      • Lansing、Michigan、アメリカ、48911
        • Great Lakes Center of Rheumatology
      • Troy、Michigan、アメリカ、48047
        • Clinical Research Institute of Michigan, LLC
    • New York
      • Great Neck、New York、アメリカ、11021
        • Northwell Health Division of Rheumatology
      • New York、New York、アメリカ、10032
        • Columbia University Medical Center
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28204
        • Joint & Muscle Research Institute
    • Ohio
      • Columbus、Ohio、アメリカ、43212
        • The Ohio State University Wexner Medical Center
      • Middleburg Heights、Ohio、アメリカ、44130
        • Paramount Medical Research & Consulting, LLC
    • Texas
      • Colleyville、Texas、アメリカ、76034
        • Precision Comprehensive Clinical Research Solutions
      • El Paso、Texas、アメリカ、79902
        • Texas Arthritis Center
      • Houston、Texas、アメリカ、77054
        • Prolato Clinical Research Center
      • Buenos Aires、アルゼンチン、C1015ABO
        • Organizacion Medica de Investigacion
      • Buenos Aires、アルゼンチン、C1111AAJ
        • DOM Centro de Reumatología
      • San Miguel、アルゼンチン、T4000AXL
        • Centro de Investigaciones Médicas Tucuman
      • Cambridge、イギリス、CB2 2QQ
        • Addenbrooke'S Hospital
      • Leeds、イギリス、LS1 3EX
        • Chapel Allerton Hospital
      • London、イギリス、SE1 9RT
        • Guy's Hospital
      • London、イギリス、NW3 2QG
        • Royal Free Hospital
      • Manchester、イギリス、M13 9WL
        • Manchester Royal Infirmary
    • Lazio
      • Rome、Lazio、イタリア、00168
        • Policlinico Universitario Agostino Gemelli
    • Lombardy
      • Milan、Lombardy、イタリア、20132
        • IRCCS S. Raffaele
    • Tuscany
      • Pisa、Tuscany、イタリア、56126
        • A.O. Universitaria Pisana
    • Veneto
      • Cona (Ferrara)、Veneto、イタリア、44124
        • Azienda Ospedaliero-Universitaria Di Ferrara Arcispedale Santanna
      • Padova、Veneto、イタリア、35128
        • Uni Di Padova
      • Barcelona、スペイン、08035
        • Hospital Universitario Vall d'Hebron
      • Madrid、スペイン、28007
        • Hospital General Universitario Gregorio Marañon
      • Prague、チェコ、128 50
        • Revmatologicky Ustav
      • Auckland、ニュージーランド、2025
        • Middlemore Hospital
      • Wellington、ニュージーランド、0621
        • Wellington Hospital
      • Paris、フランス、75651
        • Ch Pitie Salpetriere
    • Estado de Bahia
      • Salvador、Estado de Bahia、ブラジル、40150-150
        • Ser Servicos Especializados Em Reumatologia
    • Minas Gerais
      • Belo Horizonte、Minas Gerais、ブラジル、30130-100
        • Hospital das Clinicas - UFMG
      • Belo Horizonte、Minas Gerais、ブラジル、30150-221
        • Santa Casa de Misericordia
      • Juiz de Fora、Minas Gerais、ブラジル、36010-570
        • Centro Mineiro de Pesquisa - CMIP
    • Paraná
      • Curtiba、Paraná、ブラジル、80030-110
        • Centro de Estudos em Terapias Inovadoras ? CETI
    • São Paulo
      • Ribeirão Preto、São Paulo、ブラジル、14051-140
        • Hospital das Clinicas - FMUSP Ribeirao Preto
      • São Bernardo do Campo、São Paulo、ブラジル、09715-090
        • Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*
      • Arequipa、ペルー、04000
        • Hogar Clínica San Juan de Dios
      • Lima、ペルー
        • Instituto de Ginecología y Reproducción
      • Lima、ペルー、15431
        • Clínica San Juan Bautista CSJB
      • San Isidro、ペルー、L27 Lima
        • Clinica El Golf
      • Trujillo、ペルー、13008
        • Clinica San Antonio;Investigaciones Trujillo S.A.C.
      • Bydgoszcz、ポーランド、85-168
        • Szpital Uniwersytecki
      • Poznan、ポーランド、61-397
        • Prywatna Praktyka Lekarska
      • Poznan、ポーランド、61-545
        • Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM
      • Poznan、ポーランド、60-218
        • Medyczne Centrum Hetmanska
      • Warsaw、ポーランド、02-118
        • Rheuma Medicus Zaklad Opieki Zdrowotnej
      • Warsaw、ポーランド、00-874
        • MICS Centrum Medyczne Warszawa
      • Wroc?aw、ポーランド、52-210
        • REUMATOP Grzegorz Rozumek, Karin Pistorius Spó?ka Jawna
    • Coahuila
      • Torreón、Coahuila、メキシコ、27000
        • Centro de Investigacion Alberto Bazzoni S.A. de C.V.
    • Estado de Baja California
      • Mexicali、Estado de Baja California、メキシコ、21100
        • Unidad de Reumatologia Rehabilitacion Integral
    • Mexico CITY (federal District)
      • Mexico City、Mexico CITY (federal District)、メキシコ、11850
        • Centro de Investigación y Tratamiento Reumatológico S.C.
    • Nuevo León
      • Monterrey、Nuevo León、メキシコ、64460
        • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    • Bashkortostan Republic
      • Ufa、Bashkortostan Republic、ロシア、450005
        • Republican clinical hospital named after G.G. Kuvatov
    • Moscow Oblast
      • Moscow、Moscow Oblast、ロシア、115522
        • Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
    • Sankt-Peterburg
      • Saint Petersburg、Sankt-Peterburg、ロシア、197341
        • FGBU ?Federal Medical and Research Center named after V.A.Almazov? Russian Ministry of Health
      • Cape Town、南アフリカ、7500
        • Panorama Medical Center
      • Pretoria、南アフリカ、0002
        • Emmed Research
      • Somerset West、南アフリカ、7130
        • Clinical Trials Network Helderberg
      • Umhlanga、南アフリカ、4319
        • Dr Asokan Naidoo

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria >=12 weeks prior to screening
  • Anti-nuclear antibody (ANA) >=1:80, or anti-dsDNA and/or anti-Sm antibodies above the upper limit of normal (ULN), as determined by the central laboratory at screening
  • Low C3 or low C4 or low CH50 complement as determined by the central laboratory at screening
  • High disease activity at screening, based on; BILAG-2004 (Category A disease in >=1 organ system and/or Category B disease in >=2 organ systems), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (score >=8) and Physician's Global Assessment (PGA) (score >=1.0 on a 0 to 3 visual analogue scale [VAS])
  • High disease activity on Day 1, based on; SLEDAI-2K (score >=8) and PGA (score >=1.0 on a 0 to 3 VAS)
  • Current receipt of >=1 of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroid (OCS), antimalarials, conventional immunosuppressants
  • Other inclusion criteria may apply
  • The Medical Monitor may be consulted if there are any questions related to eligibility criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Presence of significant lupus-associated renal disease and/or renal impairment
  • Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
  • Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
  • Known active infection of any kind or recent major episode of infection
  • Intolerance or contraindication to study therapies
  • Other exclusion criteria may apply

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Obinutuzumab

Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.

Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.

他の名前:
  • ガジバ、GA101、RO5072759

Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

Diphenhydramine 50 mg will be administered as premedication prior to infusions.

Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.

プラセボコンパレーター:Placebo

Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.

Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

Diphenhydramine 50 mg will be administered as premedication prior to infusions.

Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.

Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52
時間枠:At Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by >=1 new British Isles Lupus Assessment Group (BILAG) A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52
時間枠:At Week 52

Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52
時間枠:From Week 40 through Week 52

Sustained OCS was defined as all of the following: 1) No treatment with prednisone >7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

From Week 40 through Week 52
Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52
時間枠:From Week 40 Through Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

From Week 40 Through Week 52
Percentage of Participants With SRI(6) Response at Week 52
時間枠:At Week 52

Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Time to BILAG Flare Over 52 Weeks
時間枠:At Week 52

BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare.

At Week 52
Percentage of Participants Who Achieved SRI(4) at Week 24
時間枠:At Week 24

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 24
Percentage of Participants Who Achieved Clinical SRI(4) at Week 52
時間枠:At Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids
時間枠:At Week 52

Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of >=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS; 4) Prednisone <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52
時間枠:At Week 52

LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K <=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS <=1; 4) Current prednisone dose <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52
時間枠:At Week 52

DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS <0.5; 3) Current prednisone dose <=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders.

At Week 52
Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52
時間枠:Baseline, Weeks 24 and 52

The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model.

Baseline, Weeks 24 and 52
Change in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52
時間枠:Baseline, Weeks 24 and 52

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Baseline, Weeks 24 and 52
Change in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52
時間枠:Baseline, Weeks 24 and 52

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Baseline, Weeks 24 and 52
Change in Active Joint Count From Baseline to Weeks 24 and 52
時間枠:Baseline, Weeks 24 and 52

Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline
時間枠:At Weeks 24, 28, 32, 36, 40, 44, 48 and 52

Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit
時間枠:At Weeks 24, 28, 32, 36, 40, 44, 48 and 52

CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52
時間枠:From Week 40 through Week 52

Sustained OCS was defined as all of the following: 1) No treatment with prednisone >5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

From Week 40 through Week 52
Cumulative Corticosteroid Use Through Week 52
時間枠:Up to Week 52

Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant.

Up to Week 52
Annualized Flare Rate Through Week 52
時間枠:Up to Week 52

BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period).

Up to Week 52
Number of Participants With Adverse Events (AEs)
時間枠:Up to Week 52

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

Up to Week 52
Number of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia
時間枠:Up to Week 52

AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade >=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions.

Up to Week 52
Maximum Serum Concentration (Cmax) of Obinutuzumab
時間枠:From Weeks 0-24 and Weeks 24-52

Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here.

From Weeks 0-24 and Weeks 24-52
Trough Concentration (Ctrough) of Obinutuzumab
時間枠:From Weeks 0-24 and Weeks 24-52

Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals.

From Weeks 0-24 and Weeks 24-52
Area Under the Concentration-time Curve (AUC) of Obinutuzumab
時間枠:Week 0-52

AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks.

Week 0-52
Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab
時間枠:Up to Week 52

Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

Up to Week 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Trials、Hoffmann-La Roche

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年10月26日

一次修了 (実際)

2025年9月15日

研究の完了 (推定)

2028年3月13日

試験登録日

最初に提出

2021年7月7日

QC基準を満たした最初の提出物

2021年7月7日

最初の投稿 (実際)

2021年7月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する